{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:50:36Z","timestamp":1778673036655,"version":"3.51.4"},"reference-count":255,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40257-025-00961-9","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T04:49:08Z","timestamp":1751950148000},"page":"923-951","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety of Alopecia Treatments in Patients with Breast Cancer and High-Risk Women: A Review"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9851-1276","authenticated-orcid":false,"given":"Caitlin A.","family":"Kearney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna L.","family":"Brinks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carli D.","family":"Needle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Rachko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy K.","family":"Bieber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario E.","family":"Lacouture","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Majerson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen I.","family":"Lo Sicco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"issue":"3","key":"961_CR1","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1053\/sonc.2000.8110","volume":"16","author":"RE Gross","year":"2000","unstructured":"Gross RE. Breast cancer: risk factors, screening, and prevention. Semin Oncol Nurs. 2000;16(3):176\u201384.","journal-title":"Semin Oncol Nurs"},{"issue":"1","key":"961_CR2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1524-4741.2008.00665.x","volume":"15","author":"GF Schwartz","year":"2009","unstructured":"Schwartz GF, Hughes KS, Lynch HT, Fabian CJ, Fentiman IS, Robson ME, et al. Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April 2007. Breast J. 2009;15(1):4\u201316.","journal-title":"Breast J"},{"issue":"4","key":"961_CR3","first-page":"474","volume":"237","author":"SE Singletary","year":"2003","unstructured":"Singletary SE. Rating the risk factors for breast cancer. Ann Surg. 2003;237(4):474\u201382.","journal-title":"Ann Surg"},{"issue":"3","key":"961_CR4","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000036905","volume":"103","author":"EI Obeagu","year":"2024","unstructured":"Obeagu EI, Obeagu GU. Breast cancer: a review of risk factors and diagnosis. Medicine (Baltimore). 2024;103(3): e36905.","journal-title":"Medicine (Baltimore)"},{"issue":"22","key":"961_CR5","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1001\/jama.2024.5534","volume":"331","author":"UPST Force","year":"2024","unstructured":"Force UPST. Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2024;331(22):1918\u201330.","journal-title":"JAMA"},{"key":"961_CR6","unstructured":"Drug Approvals and Databases. U.S. Food and Drug Administration. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/drug-approvals-and-databases."},{"issue":"5","key":"961_CR7","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jaad.2015.12.055","volume":"74","author":"S Va\u00f1\u00f3-Galv\u00e1n","year":"2016","unstructured":"Va\u00f1\u00f3-Galv\u00e1n S, Hermosa-Gelbard \u00c1, S\u00e1nchez-Neila N, Miguel-G\u00f3mez L, Saceda-Corralo D, Rodrigues-Barata R, et al. Treatment of recalcitrant adult alopecia areata universalis with oral azathioprine. J Am Acad Dermatol. 2016;74(5):1007\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"961_CR8","first-page":"264","volume":"15","author":"I Bardek","year":"2007","unstructured":"Bardek I, Milavec-Pureti\u0107 V, Lipozenci\u0107 J. Azathioprine in dermatology. Acta Dermatovenerol Croat. 2007;15(4):264\u20138.","journal-title":"Acta Dermatovenerol Croat"},{"issue":"11","key":"961_CR9","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/aje\/kws375","volume":"177","author":"B Pasternak","year":"2013","unstructured":"Pasternak B, Svanstr\u00f6m H, Schmiegelow K, Jess T, Hviid A. Use of azathioprine and the risk of cancer in inflammatory bowel disease. Am J Epidemiol. 2013;177(11):1296\u2013305.","journal-title":"Am J Epidemiol"},{"issue":"7","key":"961_CR10","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1038\/ajg.2009.745","volume":"105","author":"RG Armstrong","year":"2010","unstructured":"Armstrong RG, West J, Card TR. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case\u2013control study. Off J Am Coll Gastroenterol. 2010;105(7):1604\u20139.","journal-title":"Off J Am Coll Gastroenterol."},{"issue":"10","key":"961_CR11","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1002\/art.39738","volume":"68","author":"R Mamtani","year":"2016","unstructured":"Mamtani R, Clark AS, Scott FI, Brensinger CM, Boursi B, Chen L, et al. Association between breast cancer recurrence and immunosuppression in rheumatoid arthritis and inflammatory bowel disease: a cohort study. Arthritis Rheumatol. 2016;68(10):2403\u201311.","journal-title":"Arthritis Rheumatol"},{"key":"961_CR12","unstructured":"Sebela Pharmaceuticals Inc. IMURAN (azathioprine) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/016324s040lbl.pdf. Revised July 2024. Accessed 4 Jan 2025."},{"issue":"1","key":"961_CR13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jaad.2017.04.1142","volume":"78","author":"LC Strazzulla","year":"2018","unstructured":"Strazzulla LC, Wang EHC, Avila L, Lo Sicco K, Brinster N, Christiano AM, et al. Alopecia areata: An appraisal of new treatment approaches and overview of current therapies. J Am Acad Dermatol. 2018;78(1):15\u201324.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"961_CR14","volume":"11","author":"W Liu","year":"2024","unstructured":"Liu W, Wang L, Meng D, Hong C, Zhang Q, Yang J. Effectiveness of topical corticosteroids on the prevention of acute radiation dermatitis in patients with breast cancer: An updated systematic review and meta-analysis. Asia Pac J Oncol Nurs. 2024;11(9): 100553.","journal-title":"Asia Pac J Oncol Nurs"},{"issue":"7","key":"961_CR15","first-page":"382","volume":"31","author":"S Tam","year":"2023","unstructured":"Tam S, Zhou G, Trombetta M, Caini S, Ryan Wolf J, van den Hurk C, et al. Topical corticosteroids for the prevention of severe radiation dermatitis: a systematic review and meta-analysis. Support Care Cancer. 2023;31(7):382.","journal-title":"Support Care Cancer"},{"issue":"10","key":"961_CR16","first-page":"5343","volume":"37","author":"F Haruna","year":"2017","unstructured":"Haruna F, Lipsett A, Marignol L. Topical management of acute radiation dermatitis in breast cancer patients: a systematic review and meta-analysis. Anticancer Res. 2017;37(10):5343\u201353.","journal-title":"Anticancer Res"},{"issue":"11","key":"961_CR17","first-page":"2267","volume":"25","author":"MH Gollob","year":"1998","unstructured":"Gollob MH, Dekoven JG, Bell MJ, Assaad D, Rao J. Postradiation morphea. J Rheumatol. 1998;25(11):2267\u20139.","journal-title":"J Rheumatol"},{"issue":"4","key":"961_CR18","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/1055-9965.EPI-04-0488","volume":"14","author":"HT S\u00f8rensen","year":"2005","unstructured":"S\u00f8rensen HT, Mellemkj\u00e6r L, Skriver MV, Lash TL, Olsen JH, Baron JA. No excess risk of breast cancer among female users of systemic glucocorticoids. Cancer Epidemiol Biomark Prev. 2005;14(4):1022\u20133.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"1","key":"961_CR19","doi-asserted-by":"crossref","first-page":"R21","DOI":"10.1186\/bcr3106","volume":"14","author":"GV S\u00f8rensen","year":"2012","unstructured":"S\u00f8rensen GV, Cronin-Fenton DP, S\u00f8rensen HT, Ulrichsen SP, Pedersen L, Lash TL. Use of glucocorticoids and risk of breast cancer: a Danish population-based case-control study. Breast Cancer Res. 2012;14(1):R21.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"961_CR20","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12916-021-02004-6","volume":"19","author":"M Cairat","year":"2021","unstructured":"Cairat M, Al Rahmoun M, Gunter MJ, Heudel PE, Severi G, Dossus L, et al. Use of systemic glucocorticoids and risk of breast cancer in a prospective cohort of postmenopausal women. BMC Med. 2021;19(1):186.","journal-title":"BMC Med"},{"key":"961_CR21","unstructured":"Safarini OA, Keshavamurthy C, Patel P. Calcineurin inhibitors. StatPearls [Internet]: StatPearls Publishing; 2023."},{"issue":"3","key":"961_CR22","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1080\/09546634.2021.1886230","volume":"33","author":"H Husein-ElAhmed","year":"2022","unstructured":"Husein-ElAhmed H, Steinhoff M. Efficacy and predictive factors of cyclosporine A in alopecia areata: a systematic review with meta-analysis. J Dermatol Treat. 2022;33(3):1643\u201351.","journal-title":"J Dermatol Treat"},{"issue":"1","key":"961_CR23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jaad.2020.03.004","volume":"83","author":"N Meah","year":"2020","unstructured":"Meah N, Wall D, York K, Bhoyrul B, Bokhari L, Sigall DA, et al. The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata. J Am Acad Dermatol. 2020;83(1):123\u201330.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"961_CR24","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jaad.2019.04.053","volume":"81","author":"VWY Lai","year":"2019","unstructured":"Lai VWY, Chen G, Gin D, Sinclair R. Cyclosporine for moderate-to-severe alopecia areata: a double-blind, randomized, placebo-controlled clinical trial of efficacy and safety. J Am Acad Dermatol. 2019;81(3):694\u2013701.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"961_CR25","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0190-9622(98)70325-1","volume":"39","author":"M Lebwohl","year":"1998","unstructured":"Lebwohl M, Ellis C, Gottlieb A, Koo J, Krueger G, Linden K, et al. Cyclosporine consensus conference: With emphasis on the treatment of psoriasis. J Am Acad Dermatol. 1998;39(3):464\u201375.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"961_CR26","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jaad.2010.02.062","volume":"63","author":"C Ryan","year":"2010","unstructured":"Ryan C, Amor KT, Menter A. The use of cyclosporine in dermatology: part II. J Am Acad Dermatol. 2010;63(6):949\u201372.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"961_CR27","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jaad.2020.02.044","volume":"82","author":"A Menter","year":"2020","unstructured":"Menter A, Gelfand JM, Connor C, Armstrong AW, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82(6):1445\u201386.","journal-title":"J Am Acad Dermatol"},{"key":"961_CR28","unstructured":"Novartis Pharmaceuticals Corporation. NEORAL (cyclosporine) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/050715s041,050716s041,050735s003,050736s001,050737s003,050738s001lbl.pdf. Revised Semptember 2023. Accessed 5 Jan 2025."},{"key":"961_CR29","unstructured":"Novartis Pharmaceuticals Corporation. SANDIMMUNE (cyclosporine) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/050573s039,050574s047,050625s053lbl.pdf. Revised Semptember 2023. Accessed 5 Jan 2025."},{"issue":"8978","key":"961_CR30","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0140-6736(95)91618-0","volume":"346","author":"T Stewart","year":"1995","unstructured":"Stewart T, Tsai SC, Grayson H, Henderson R, Opelz G. Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. The Lancet. 1995;346(8978):796\u20138.","journal-title":"The Lancet"},{"issue":"2","key":"961_CR31","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3892\/ijmm.2012.989","volume":"30","author":"K Jiang","year":"2012","unstructured":"Jiang K, He B, Lai L, Chen Q, Liu Y, Guo Q, et al. Cyclosporine A inhibits breast cancer cell growth by downregulating the expression of pyruvate kinase subtype M2. Int J Mol Med. 2012;30(2):302\u20138.","journal-title":"Int J Mol Med"},{"key":"961_CR32","unstructured":"Institute NC. Evaluating the Effects of Cyclosporine A on Cancer Growth Markers in Patients with DNA Repair Defective Triple-negative Breast Cancer. 2024 [cited; Available from: https:\/\/www.cancer.gov\/research\/participate\/clinical-trials-search\/v?id=NCI-2024-01558&r=1. Accessed 15 Nov 2024."},{"issue":"4","key":"961_CR33","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/bcr2889","volume":"13","author":"DL Holliday","year":"2011","unstructured":"Holliday DL, Speirs V. Choosing the right cell line for breast cancer research. Breast Cancer Res. 2011;13(4):215.","journal-title":"Breast Cancer Res"},{"issue":"2","key":"961_CR34","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/jidsymp.2015.33","volume":"17","author":"KG Bulock","year":"2015","unstructured":"Bulock KG, Cardia JP, Pavco PA, Levis WR. Diphencyprone treatment of alopecia areata: postulated mechanism of action and prospects for therapeutic synergy with RNA interference. J Investig Dermatol Symp Proc. 2015;17(2):16\u20138.","journal-title":"J Investig Dermatol Symp Proc"},{"key":"961_CR35","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jdcr.2024.04.012","volume":"48","author":"DD Desai","year":"2024","unstructured":"Desai DD, Buontempo MG, Nohria A, Alhanshali L, Lo Sicco K, Shapiro J. Use of diphenylcyclopropenone for alopecia areata treatment during pregnancy. JAAD Case Rep. 2024;48:88\u20139.","journal-title":"JAAD Case Rep."},{"issue":"8","key":"961_CR36","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.3906\/sag-1807-230","volume":"50","author":"Z Kutlubay","year":"2020","unstructured":"Kutlubay Z, Sevim A, Ayd\u0131n \u00d6, Vehid S, Serdaro\u011flu S. Assessment of treatment efficacy of diphenylcyclopropenone (DPCP) for alopecia areata. Turk J Med Sci. 2020;50(8):1817\u201324.","journal-title":"Turk J Med Sci."},{"issue":"4","key":"961_CR37","doi-asserted-by":"crossref","first-page":"312","DOI":"10.2340\/0001555574314316","volume":"74","author":"J Berth-Jones","year":"1994","unstructured":"Berth-Jones J, Mc Burney A, Hutchinson PE. Diphencyprone is not detectable in serum or urine following topical application. Acta Derm Venereol. 1994;74(4):312\u20133.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"961_CR38","doi-asserted-by":"crossref","first-page":"6073889","DOI":"10.1155\/2023\/6073889","volume":"2023","author":"J Zhu","year":"2023","unstructured":"Zhu J, Qiao R, Li Y, Lan X, Gong X, Jiang Y. The efficacy, safety, and recurrence rate of diphenylcyclopropenone topical immunotherapy for alopecia areata: a systemic review and meta-analysis. Dermatol Therapy. 2023;2023(1):6073889.","journal-title":"Dermatol Therapy."},{"issue":"5","key":"961_CR39","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/CMR.0000000000000914","volume":"33","author":"JP Pham","year":"2023","unstructured":"Pham JP, Dwyer L, Phan K, Menzies AM, Frew JW. Efficacy of topical diphencyprone for melanoma in-transit metastases: a systematic review and meta-analysis. Melanoma Res. 2023;33(5):434\u20136.","journal-title":"Melanoma Res"},{"issue":"1","key":"961_CR40","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000381912","volume":"231","author":"JW Byun","year":"2015","unstructured":"Byun JW, Moon JH, Bang CY, Shin J, Choi GS. Effectiveness of 308-nm excimer laser therapy in treating alopecia areata, determined by examining the treated sides of selected alopecic patches. Dermatology. 2015;231(1):70\u20136.","journal-title":"Dermatology"},{"issue":"4","key":"961_CR41","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jaad.2023.10.071","volume":"91","author":"M Yaghi","year":"2024","unstructured":"Yaghi M, McMullan P, Truong TM, Rothe M, Murase J, Grant-Kels JM. Safety of dermatologic medications in pregnancy and lactation: an update-Part II: Lactation. J Am Acad Dermatol. 2024;91(4):651\u201368.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"961_CR42","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316\u201326.","journal-title":"N Engl J Med"},{"key":"961_CR43","doi-asserted-by":"crossref","unstructured":"Beydon M, Pinto S, De Rycke Y, Fautrel B, Mariette X, Seror R, et al. Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort study. Lancet Reg Health Eur. 2023;35.","DOI":"10.1016\/j.lanepe.2023.100768"},{"issue":"7","key":"961_CR44","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/ard-2022-223715","volume":"82","author":"LE Kristensen","year":"2023","unstructured":"Kristensen LE, Danese S, Yndestad A, Wang C, Nagy E, Modesto I, et al. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis. 2023;82(7):901\u201310.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"961_CR45","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/ard-2022-222543","volume":"82","author":"JR Curtis","year":"2023","unstructured":"Curtis JR, Yamaoka K, Chen YH, Bhatt DL, Gunay LM, Sugiyama N, et al. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2023;82(3):331\u201343.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"961_CR46","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1002\/cam4.1448","volume":"7","author":"CC Chen","year":"2018","unstructured":"Chen CC, Chang YT, Liu HN, Chen YJ. Cancer risk in patients with alopecia areata: a nationwide population-based matched cohort study. Cancer Med. 2018;7(5):2153\u20139.","journal-title":"Cancer Med"},{"issue":"1","key":"961_CR47","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jaad.2017.08.011","volume":"78","author":"H-M Seo","year":"2018","unstructured":"Seo H-M, Han SS, Kim JS. Cancer risks among patients with alopecia areata: a population-based case-control study in Korea. J Am Acad Dermatol. 2018;78(1):209\u201311.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"961_CR48","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s00403-024-03385-3","volume":"316","author":"K Kridin","year":"2024","unstructured":"Kridin K, Laufer-Britva R, Jimenez F, Cohen AD, Kaplan B, Lyakhovitsky A. Alopecia areata and malignancies: uncertainties clarified by a large-scale population-based study. Arch Dermatol Res. 2024;316(10):678.","journal-title":"Arch Dermatol Res"},{"issue":"18","key":"961_CR49","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687\u201399.","journal-title":"N Engl J Med"},{"issue":"10387","key":"961_CR50","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b\u20133 trial. The Lancet. 2023;401(10387):1518\u201329.","journal-title":"The Lancet"},{"issue":"5","key":"961_CR51","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jaad.2024.06.097","volume":"91","author":"B King","year":"2024","unstructured":"King B, Senna MM, Mesinkovska NA, Lynde C, Zirwas M, Maari C, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1). J Am Acad Dermatol. 2024;91(5):880\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"961_CR52","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","volume":"156","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863\u201373.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"961_CR53","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bjd.18898","volume":"183","author":"E Simpson","year":"2020","unstructured":"Simpson E, Lacour JP, Spelman L, Galimberti R, Eichenfield L, Bissonnette R, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242\u201355.","journal-title":"Br J Dermatol"},{"issue":"10","key":"961_CR54","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1001\/jamadermatol.2021.2830","volume":"157","author":"LF Eichenfield","year":"2021","unstructured":"Eichenfield LF, Flohr C, Sidbury R, Siegfried E, Szalai Z, Galus R, et al. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial. JAMA Dermatol. 2021;157(10):1165\u201373.","journal-title":"JAMA Dermatol"},{"issue":"9","key":"961_CR55","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","volume":"157","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157(9):1047\u201355.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"961_CR56","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","volume":"384","author":"T Bieber","year":"2021","unstructured":"Bieber T, Simpson EL, Silverberg JI, Tha\u00e7i D, Paul C, Pink AE, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101\u201312.","journal-title":"N Engl J Med"},{"issue":"1","key":"961_CR57","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","volume":"86","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Silverberg JI, Lynde CW, Bieber T, Eisman S, Zdybski J, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol. 2022;86(1):104\u201312.","journal-title":"J Am Acad Dermatol"},{"issue":"10290","key":"961_CR58","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. The Lancet. 2021;397(10290):2151\u201368.","journal-title":"The Lancet"},{"issue":"10246","key":"961_CR59","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet. 2020;396(10246):255\u201366.","journal-title":"The Lancet"},{"issue":"3","key":"961_CR60","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/bjd.21630","volume":"187","author":"T Bieber","year":"2022","unstructured":"Bieber T, Reich K, Paul C, Tsunemi Y, Augustin M, Lacour JP, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4). Br J Dermatol. 2022;187(3):338\u201352.","journal-title":"Br J Dermatol"},{"issue":"1","key":"961_CR61","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s13555-022-00842-7","volume":"13","author":"N Katoh","year":"2023","unstructured":"Katoh N, Ohya Y, Murota H, Ikeda M, Hu X, Ikeda K, et al. Safety and efficacy of upadacitinib for atopic dermatitis in Japan: 2-year interim results from the phase 3 Rising Up Study. Dermatol Therapy. 2023;13(1):221\u201334.","journal-title":"Dermatol Therapy."},{"issue":"1","key":"961_CR62","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaad.2021.02.028","volume":"85","author":"EL Simpson","year":"2021","unstructured":"Simpson EL, Forman S, Silverberg JI, Zirwas M, Maverakis E, Han G, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis: results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5). J Am Acad Dermatol. 2021;85(1):62\u201370.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"961_CR63","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/bjd\/ljad096","volume":"189","author":"A Torrelo","year":"2023","unstructured":"Torrelo A, Rewerska B, Galimberti M, Paller A, Yang C-Y, Prakash A, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). Br J Dermatol. 2023;189(1):23\u201332.","journal-title":"Br J Dermatol"},{"issue":"4","key":"961_CR64","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.14018","volume":"173","author":"K Papp","year":"2015","unstructured":"Papp K, Menter M, Abe M, Elewski B, Feldman S, Gottlieb A, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015;173(4):949\u201361.","journal-title":"Br J Dermatol"},{"issue":"4","key":"961_CR65","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","volume":"85","author":"K Papp","year":"2021","unstructured":"Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Leung DY, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021;85(4):863\u201372.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"961_CR66","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jdermsci.2017.05.004","volume":"88","author":"J Zhang","year":"2017","unstructured":"Zhang J, Tsai T-F, Lee M-G, Zheng M, Wang G, Jin H, et al. The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: a phase 3, randomized, double-blind, placebo-controlled study. J Dermatol Sci. 2017;88(1):36\u201345.","journal-title":"J Dermatol Sci"},{"issue":"10290","key":"961_CR67","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2021;397(10290):2169\u201381.","journal-title":"The Lancet"},{"issue":"10348","key":"961_CR68","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","volume":"400","author":"K Reich","year":"2022","unstructured":"Reich K, Thyssen JP, Blauvelt A, Eyerich K, Soong W, Rice ZP, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. The Lancet. 2022;400(10348):273\u201382.","journal-title":"The Lancet"},{"issue":"8","key":"961_CR69","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/ard-2023-224049","volume":"82","author":"MD Russell","year":"2023","unstructured":"Russell MD, Stovin C, Alveyn E, Adeyemi O, Chan CKD, Patel V, et al. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications. Ann Rheum Dis. 2023;82(8):1059\u201367.","journal-title":"Ann Rheum Dis"},{"key":"961_CR70","doi-asserted-by":"crossref","unstructured":"Bezzio C, Vernero M, Ribaldone DG, Alimenti E, Manes G, Saibeni S. Cancer risk in patients treated with the JAK inhibitor tofacitinib: systematic review and meta-Analysis. Cancers (Basel). 2023;15(8).","DOI":"10.3390\/cancers15082197"},{"issue":"1","key":"961_CR71","doi-asserted-by":"crossref","first-page":"12258","DOI":"10.1038\/ncomms12258","volume":"7","author":"A Bottos","year":"2016","unstructured":"Bottos A, Gotthardt D, Gill JW, Gattelli A, Frei A, Tzankov A, et al. Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models. Nat Commun. 2016;7(1):12258.","journal-title":"Nat Commun"},{"key":"961_CR72","doi-asserted-by":"crossref","unstructured":"Kearney CA, Needle CD, Brinks AL, Gutierrez D, Lo Sicco KI. Response to Sood et al's. Systemic Janus kinase inhibitor treatment for vitiligo: an evidence-based review. J Am Acad Dermatol. 2025;92(5):e155\u2013e6.","DOI":"10.1016\/j.jaad.2025.01.059"},{"issue":"3","key":"961_CR73","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jaad.2023.11.027","volume":"90","author":"CD Needle","year":"2024","unstructured":"Needle CD, Klein EJ, Gjonaj J, Nohria A, Karim M, Liu L, et al. Comparison of comorbidities and adverse events in dermatology and rheumatology patients prescribed tofacitinib: A retrospective analysis. J Am Acad Dermatol. 2024;90(3):659\u201362.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"961_CR74","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamadermatol.2023.4090","volume":"160","author":"JP Ingrassia","year":"2024","unstructured":"Ingrassia JP, Maqsood MH, Gelfand JM, Weber BN, Bangalore S, Lo Sicco KI, et al. Cardiovascular and venous thromboembolic risk With JAK inhibitors in immune-mediated inflammatory skin diseases: a systematic review and meta-analysis. JAMA Dermatol. 2024;160(1):28\u201336.","journal-title":"JAMA Dermatol"},{"issue":"9","key":"961_CR75","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ad.2023.06.012","volume":"114","author":"L Corbella-Bagot","year":"2023","unstructured":"Corbella-Bagot L, Riquelme-McLoughlin C, Morgado-Carrasco D. Long-term safety profile and off-label use of JAK inhibitors in dermatological disorders. Actas Dermosifiliogr. 2023;114(9):784\u2013801.","journal-title":"Actas Dermosifiliogr"},{"issue":"6","key":"961_CR76","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1039\/D0MD00051E","volume":"11","author":"V Yang","year":"2020","unstructured":"Yang V, Gouveia MJ, Santos J, Koksch B, Amorim I, G\u00e4rtner F, et al. Breast cancer: insights in disease and influence of drug methotrexate. RSC Med Chem. 2020;11(6):646\u201364.","journal-title":"RSC Med Chem."},{"issue":"3","key":"961_CR77","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jaad.2024.05.037","volume":"91","author":"RS Raval","year":"2024","unstructured":"Raval RS, Nohria A, Desai D, Mourtzanakis K, Buontempo M, Shapiro J, et al. The use of minoxidil in the treatment of alopecia areata: A systematic review. J Am Acad Dermatol. 2024;91(3):508\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"961_CR78","unstructured":"Patel P, Nessel TA, Kumar DD. Minoxidil. StatPearls [Internet]. Treasure Island, Florida: StatPearls Publishing; [Updated February 24 2024]."},{"issue":"5","key":"961_CR79","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jaad.2022.12.005","volume":"88","author":"J Kang","year":"2023","unstructured":"Kang J, Lee JW, Kwon O. Efficacy of low-dose oral minoxidil in the management of anticancer therapy-induced alopecia in patients with breast cancer: a retrospective cohort study. J Am Acad Dermatol. 2023;88(5):1170\u20133.","journal-title":"J Am Acad Dermatol"},{"key":"961_CR80","doi-asserted-by":"crossref","unstructured":"Kuo AM, Reingold RE, Ketosugbo KF, Pan A, Kraehenbuehl L, Dusza S, et al. Oral minoxidil for late alopecia in cancer survivors. Breast Cancer Res Treat. 2024;208(3):491\u20139.","DOI":"10.1007\/s10549-024-07440-5"},{"key":"961_CR81","doi-asserted-by":"crossref","unstructured":"Zaminski D, Sikora M, Nohria A, Desai D, Buontempo M, Caplan AS, et al. Tolerability and effectiveness of low-dose oral minoxidil for alopecia in patients with breast cancer: A retrospective cohort study. J Am Acad Dermatol. 2025;92(4):906\u20139.","DOI":"10.1016\/j.jaad.2024.11.048"},{"key":"961_CR82","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3389\/fphar.2020.00577","volume":"11","author":"D Fukushiro-Lopes","year":"2020","unstructured":"Fukushiro-Lopes D, Hegel AD, Russo A, Senyuk V, Liotta M, Beeson GC, et al. Repurposing Kir6\/SUR2 channel activator minoxidil to arrests growth of gynecologic cancers. Front Pharmacol. 2020;11:577.","journal-title":"Front Pharmacol"},{"issue":"4","key":"961_CR83","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s10585-022-10166-7","volume":"39","author":"S Qiu","year":"2022","unstructured":"Qiu S, Fraser SP, Pires W, Djamgoz MBA. Anti-invasive effects of minoxidil on human breast cancer cells: combination with ranolazine. Clin Exp Metastasis. 2022;39(4):679\u201389.","journal-title":"Clin Exp Metastasis"},{"issue":"3","key":"961_CR84","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s13555-021-00524-w","volume":"11","author":"CY Hsieh","year":"2021","unstructured":"Hsieh CY, Tsai TF. Use of H-1 antihistamine in dermatology: more than itch and urticaria control: a systematic review. Dermatol Ther (Heidelb). 2021;11(3):719\u201332.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"1","key":"961_CR85","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jdermsci.2013.04.029","volume":"72","author":"T Ito","year":"2013","unstructured":"Ito T, Fujiyama T, Hashizume H, Tokura Y. Antihistaminic drug olopatadine downmodulates T cell chemotaxis toward CXCL10 by reducing CXCR3 expression, F-actin polymerization and calcium influx in patients with alopecia areata. J Dermatol Sci. 2013;72(1):68\u201371.","journal-title":"J Dermatol Sci"},{"issue":"2","key":"961_CR86","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jdermsci.2010.03.009","volume":"58","author":"M Ohyama","year":"2010","unstructured":"Ohyama M, Shimizu A, Tanaka K, Amagai M. Experimental evaluation of ebastine, a second-generation anti-histamine, as a supportive medication for alopecia areata. J Dermatol Sci. 2010;58(2):154\u20137.","journal-title":"J Dermatol Sci"},{"issue":"6","key":"961_CR87","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1346-8138.2009.00647.x","volume":"36","author":"S Inui","year":"2009","unstructured":"Inui S, Nakajima T, Toda N, Itami S. Fexofenadine hydrochloride enhances the efficacy of contact immunotherapy for extensive alopecia areata: retrospective analysis of 121 cases. J Dermatol. 2009;36(6):323\u20137.","journal-title":"J Dermatol"},{"issue":"4","key":"961_CR88","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.jaad.2020.06.1026","volume":"84","author":"YB Lee","year":"2021","unstructured":"Lee YB, Lee W-S. Efficacy of antihistamines in combination with topical corticosteroid and superficial cryotherapy for treatment of alopecia areata: a retrospective cohort study. J Am Acad Dermatol. 2021;84(4):1152\u20134.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"961_CR89","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ijc.11240","volume":"106","author":"V Nadalin","year":"2003","unstructured":"Nadalin V, Cotterchio M, Kreiger N. Antihistamine use and breast cancer risk. Int J Cancer. 2003;106(4):566\u20138.","journal-title":"Int J Cancer"},{"issue":"8","key":"961_CR90","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/oxfordjournals.aje.a010091","volume":"150","author":"JP Kelly","year":"1999","unstructured":"Kelly JP, Rosenberg L, Palmer JR, Rao RS, Strom BL, Stolley PD, et al. Risk of breast cancer according to use of antidepressants, phenothizaines, and anthistamines. Am J Epidemiol. 1999;150(8):861\u20138.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"961_CR91","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1054\/bjoc.1999.0895","volume":"82","author":"PF Bowrey","year":"2000","unstructured":"Bowrey PF, King J, Magarey C, Schwartz P, Marr P, Bolton E, et al. Histamine, mast cells and tumour cell proliferation in breast cancer: does preoperative cimetidine administration have an effect? Br J Cancer. 2000;82(1):167\u201370.","journal-title":"Br J Cancer"},{"issue":"9","key":"961_CR92","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1080\/0284186X.2020.1769185","volume":"59","author":"I Fritz","year":"2020","unstructured":"Fritz I, Wagner P, Broberg P, Einefors R, Olsson H. Desloratadine and loratadine stand out among common H. Acta Oncol. 2020;59(9):1103\u20139.","journal-title":"Acta Oncol"},{"issue":"7","key":"961_CR93","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/jdv.14987","volume":"32","author":"S Lee","year":"2018","unstructured":"Lee S, Kim BJ, Lee CH, Lee WS. Increased prevalence of vitamin D deficiency in patients with alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2018;32(7):1214\u201321.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"961_CR94","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jaad.2017.07.051","volume":"78","author":"TY Tsai","year":"2018","unstructured":"Tsai TY, Huang YC. Vitamin D deficiency in patients with alopecia areata: A systematic review and meta-analysis. J Am Acad Dermatol. 2018;78(1):207\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"961_CR95","first-page":"5285","volume":"11","author":"X Lin","year":"2019","unstructured":"Lin X, Meng X, Song Z. Vitamin D and alopecia areata: possible roles in pathogenesis and potential implications for therapy. Am J Transl Res. 2019;11(9):5285\u2013300.","journal-title":"Am J Transl Res."},{"issue":"1","key":"961_CR96","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1634\/theoncologist.2011-0278","volume":"17","author":"T Shao","year":"2012","unstructured":"Shao T, Klein P, Grossbard ML. Vitamin D and breast cancer. Oncologist. 2012;17(1):36\u201345.","journal-title":"Oncologist"},{"key":"961_CR97","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s13555-020-00379-7","volume":"10","author":"E Molinelli","year":"2020","unstructured":"Molinelli E, Campanati A, Brisigotti V, Sapigni C, Paolinelli M, Offidani A. Efficacy and safety of topical calcipotriol 0.005% versus topical clobetasol 0.05% in the management of alopecia areata: an intrasubject pilot study. Dermatol Therapy. 2020;10:515\u201321.","journal-title":"Dermatol Therapy."},{"issue":"6","key":"961_CR98","first-page":"616","volume":"14","author":"AA Cerman","year":"2015","unstructured":"Cerman AA, Solak SS, Altunay \u0130, K\u00fc\u00e7\u00fck\u00fcnal N. Topical calcipotriol therapy for mild-to-moderate alopecia areata: a retrospective study. J Drugs Dermatol. 2015;14(6):616\u201320.","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"961_CR99","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12464","volume":"30","author":"T Narang","year":"2017","unstructured":"Narang T, Daroach M, Kumaran MS. Efficacy and safety of topical calcipotriol in management of alopecia areata: a pilot study. Dermatol Therapy. 2017;30(3): e12464.","journal-title":"Dermatol Therapy."},{"issue":"3","key":"961_CR100","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jdcr.2019.01.006","volume":"5","author":"L Krueger","year":"2019","unstructured":"Krueger L, Peterson E, Shapiro J, Lo SK. Case report of novel combination of anthralin and calcipotriene leading to trichologic response in alopecia areata. JAAD Case Rep. 2019;5(3):258\u201360.","journal-title":"JAAD Case Rep."},{"issue":"11","key":"961_CR101","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1111\/jocd.14421","volume":"20","author":"K Saini","year":"2021","unstructured":"Saini K, Mysore V. Role of vitamin D in hair loss: a short review. J Cosmet Dermatol. 2021;20(11):3407\u201314.","journal-title":"J Cosmet Dermatol"},{"issue":"6","key":"961_CR102","doi-asserted-by":"crossref","first-page":"192","DOI":"10.5409\/wjcp.v10.i6.192","volume":"10","author":"DT Papadimitriou","year":"2021","unstructured":"Papadimitriou DT, Bothou C, Dermitzaki E, Alexopoulos A, Mastorakos G. Treatment of alopecia totalis\/universalis\/focalis with vitamin D and analogs: three case reports and a literature review. World J Clin Pediatr. 2021;10(6):192\u20139.","journal-title":"World J Clin Pediatr."},{"issue":"10","key":"961_CR103","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1111\/jocd.14844","volume":"21","author":"AF Rashad","year":"2022","unstructured":"Rashad AF, Elgamal E, Fouda I. Intralesional vitamin D3 in treatment of alopecia areata: a randomized controlled clinical trial. J Cosmetic Dermatol. 2022;21(10):4617\u201322.","journal-title":"J Cosmetic Dermatol."},{"issue":"12","key":"961_CR104","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/j.ejca.2010.03.037","volume":"46","author":"L Yin","year":"2010","unstructured":"Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: serum vitamin D and breast cancer risk. Eur J Cancer. 2010;46(12):2196\u2013205.","journal-title":"Eur J Cancer"},{"issue":"11","key":"961_CR105","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1038\/bjc.2014.175","volume":"110","author":"Y Kim","year":"2014","unstructured":"Kim Y, Je Y. Vitamin D intake, blood 25 (OH) D levels, and breast cancer risk or mortality: a meta-analysis. Br J Cancer. 2014;110(11):2772\u201384.","journal-title":"Br J Cancer"},{"issue":"1","key":"961_CR106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-020-05669-4","volume":"182","author":"L Zhou","year":"2020","unstructured":"Zhou L, Chen B, Sheng L, Turner A. The effect of vitamin D supplementation on the risk of breast cancer: a trial sequential meta-analysis. Breast Cancer Res Treat. 2020;182(1):1\u20138.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"961_CR107","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1677\/erc.0.0090045","volume":"9","author":"KW Colston","year":"2002","unstructured":"Colston KW, Hansen CMr. Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocrine-Relat Cancer Endocr Relat Cancer Endocr Relat Cancer. 2002;9(1):45\u201359.","journal-title":"Endocrine-Relat Cancer Endocr Relat Cancer Endocr Relat Cancer."},{"issue":"2","key":"961_CR108","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10549-019-05392-9","volume":"178","author":"A Arnaout","year":"2019","unstructured":"Arnaout A, Robertson S, Pond GR, Vieth R, Jeong A, Hilton J, et al. Randomized window of opportunity trial evaluating high-dose vitamin D in breast cancer patients. Breast Cancer Res Treat. 2019;178(2):347\u201356.","journal-title":"Breast Cancer Res Treat"},{"key":"961_CR109","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41523-017-0006-x","volume":"3","author":"NJ Nasser","year":"2017","unstructured":"Nasser NJ, Fenig S, Ravid A, Nouriel A, Ozery N, Gardyn S, et al. Vitamin D ointment for prevention of radiation dermatitis in breast cancer patients. NPJ Breast Cancer. 2017;3:10.","journal-title":"NPJ Breast Cancer."},{"key":"961_CR110","doi-asserted-by":"crossref","unstructured":"Seyed Jafari SM, Heidemeyer K, Hunger RE, de Viragh PA. Safety of antiandrogens for the treatment of female androgenetic alopecia with respect to gynecologic malignancies. J Clin Med. 2024;13(11).","DOI":"10.3390\/jcm13113052"},{"issue":"4","key":"961_CR111","first-page":"550","volume":"41","author":"L Drake","year":"1999","unstructured":"Drake L, Hordinsky M, Fiedler V, Swinehart J, Unger WP, Cotterill PC, et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol. 1999;41(4):550\u20134.","journal-title":"J Am Acad Dermatol"},{"key":"961_CR112","unstructured":"Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, et al. Endotext [Internet]. 2000."},{"issue":"1","key":"961_CR113","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10549-018-4996-3","volume":"174","author":"RN Rozner","year":"2019","unstructured":"Rozner RN, Freites-Martinez A, Shapiro J, Geer EB, Goldfarb S, Lacouture ME. Safety of 5\u03b1-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies. Breast Cancer Res Treat. 2019;174(1):15\u201326.","journal-title":"Breast Cancer Res Treat"},{"key":"961_CR114","doi-asserted-by":"publisher","unstructured":"Kearney CA, Needle CD, Brinks AL, Shapiro J, Lacouture ME, Lo Sicco KI. Response to Venkatesh et al's \"Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: A single-center retrospective cohort study\". J Am Acad Dermatol. 2025:S0190-9622(25)00667-X. https:\/\/doi.org\/10.1016\/j.jaad.2025.03.091.","DOI":"10.1016\/j.jaad.2025.03.091"},{"key":"961_CR115","doi-asserted-by":"crossref","unstructured":"Venkatesh T, Quan VL, Li EB, Colavincenzo ML. Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: A single-center retrospective cohort study. J Am Acad Dermatol. 2025;92(1):163\u20135.","DOI":"10.1016\/j.jaad.2024.09.028"},{"key":"961_CR116","doi-asserted-by":"crossref","unstructured":"Chen LC, Hsieh TYJ, Senna MM. 5\u03b1-reductase inhibitor exposure for dermatologic conditions does not increase the risk of female breast or gynecologic cancers: A population-based propensity score-matched cohort study. J Am Acad Dermatol. 2025;92(2):343\u20135.","DOI":"10.1016\/j.jaad.2024.10.023"},{"key":"961_CR117","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jdcr.2023.02.021","volume":"35","author":"C Dubin","year":"2023","unstructured":"Dubin C, Lamb A. Hair regrowth in endocrine therapy alopecia with dutasteride treatment in woman with estrogen positive breast cancer. JAAD Case Rep. 2023;35:5\u20137.","journal-title":"JAAD Case Rep."},{"issue":"5","key":"961_CR118","first-page":"2250","volume":"86","author":"T Suzuki","year":"2001","unstructured":"Suzuki T, Darnel AD, Akahira JI, Ariga N, Ogawa S, Kaneko C, et al. 5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions. J Clin Endocrinol Metab. 2001;86(5):2250\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"961_CR119","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/CEJ.0000000000000162","volume":"24","author":"S Lehrer","year":"2015","unstructured":"Lehrer S. Finasteride for postmenopausal breast cancer prevention. Eur J Cancer Prev. 2015;24(5):456\u20137.","journal-title":"Eur J Cancer Prev"},{"key":"961_CR120","first-page":"1","volume-title":"xPharm: the comprehensive pharmacology reference","author":"SE Bicalutamide","year":"2007","unstructured":"Bicalutamide SE. In: Enna SJ, Bylund DB, editors. xPharm: the comprehensive pharmacology reference. New York: Elsevier; 2007. p. 1\u20135."},{"key":"961_CR121","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/B978-0-7020-7167-6.00046-4","volume-title":"Medical pharmacology and therapeutics (Fifth Edition)","author":"DG Waller","year":"2018","unstructured":"Waller DG, Sampson AP. 46-Androgens, antiandrogens and anabolic steroids. In: Waller DG, Sampson AP, editors. Medical pharmacology and therapeutics (Fifth Edition). Elsevier; 2018. p. 531\u20135."},{"key":"961_CR122","unstructured":"Johnson DB, Sonthalia S. Flutamide. 2018."},{"issue":"17","key":"961_CR123","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000019822","volume":"99","author":"Y Kong","year":"2020","unstructured":"Kong Y, Qu F, Yuan X, Yan X, Yu W. Effect of Bicalutamide on the proliferation and invasion of human triple negative breast cancer MDA-MB-231 cells. Medicine (Baltimore). 2020;99(17): e19822.","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"961_CR124","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamadermatol.2021.3676","volume":"157","author":"B Bhoyrul","year":"2021","unstructured":"Bhoyrul B, Asfour L, Lutz G, Mitchell L, Jerjen R, Sinclair RD, et al. Clinicopathologic characteristics and response to treatment of persistent chemotherapy-induced alopecia in breast cancer survivors. JAMA Dermatol. 2021;157(11):1335\u201342.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"961_CR125","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40257-019-00493-z","volume":"21","author":"DH Marks","year":"2020","unstructured":"Marks DH, Prasad S, De Souza B, Burns LJ, Senna MM. Topical antiandrogen therapies for androgenetic alopecia and acne vulgaris. Am J Clin Dermatol. 2020;21(2):245\u201354.","journal-title":"Am J Clin Dermatol"},{"issue":"08","key":"961_CR126","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1055\/s-2007-1003337","volume":"24","author":"C Eil","year":"1992","unstructured":"Eil C. Ketoconazole binds to the human androgen receptor. Hormone Metab Res. 1992;24(08):367\u201370.","journal-title":"Hormone Metab Res."},{"issue":"4","key":"961_CR127","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1159\/000017954","volume":"196","author":"C Pi\u00e9rard-Franchimont","year":"1998","unstructured":"Pi\u00e9rard-Franchimont C, De Doncker P, Cauwenbergh G, Pi\u00e9rard GE. Ketoconazole shampoo: effect of long-term use in androgenic alopecia. Dermatology. 1998;196(4):474\u20137.","journal-title":"Dermatology"},{"issue":"1","key":"961_CR128","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0306-9877(03)00264-0","volume":"62","author":"BS Hugo Perez","year":"2004","unstructured":"Hugo Perez BS. Ketocazole as an adjunct to finasteride in the treatment of androgenetic alopecia in men. Med Hypoth. 2004;62(1):112\u20135.","journal-title":"Med Hypoth"},{"issue":"5","key":"961_CR129","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/0090-4295(89)90037-X","volume":"33","author":"FJ Witjes","year":"1989","unstructured":"Witjes FJ, Debruyne FMJ, Del Moral PF, Geboers ADH. Ketoconazole high dose in management of hormonally pretreated patients with progressive metastatic prostate cancer. Urology. 1989;33(5):411\u20135.","journal-title":"Urology"},{"issue":"5","key":"961_CR130","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2165\/00002018-199920050-00005","volume":"20","author":"RA Bok","year":"1999","unstructured":"Bok RA, Small EJ. The treatment of advanced prostate cancer with ketoconazole. Drug Saf. 1999;20(5):451\u20138.","journal-title":"Drug Saf"},{"issue":"4","key":"961_CR131","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/bjc.1988.247","volume":"58","author":"AL Harris","year":"1988","unstructured":"Harris AL, Cantwell BM, Dowsett M. High dose ketoconazole: endocrine and therapeutic effects in postmenopausal breast cancer. Br J Cancer. 1988;58(4):493\u20136.","journal-title":"Br J Cancer"},{"key":"961_CR132","first-page":"43","volume":"43","author":"JV Lint","year":"1988","unstructured":"Lint JV, Doncker P, Woestenborghs R. Chronic use of 2 % ketoconazole shampoo in patients with seborrheic dermatitis and dandruff: ketoconazole plasma levels and safety. Curr Therapeutic Res Clin Exp. 1988;43:43\u20137.","journal-title":"Curr Therapeutic Res Clin Exp."},{"issue":"1","key":"961_CR133","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003088-198814010-00002","volume":"14","author":"TK Daneshmend","year":"1988","unstructured":"Daneshmend TK, Warnock DW. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet. 1988;14(1):13\u201334.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"961_CR134","first-page":"43","volume":"43","author":"J Van Lint","year":"1988","unstructured":"Van Lint J, De Doncker P, Woestenborghs R. Chronic use of 2 % ketoconazole shampoo in patients with seborrheic dermatitis and dandruff: ketoconazole plasma levels and safety. Curr Therapeutic Res. 1988;43(1):43\u20137.","journal-title":"Curr Therapeutic Res."},{"key":"961_CR135","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.oraloncology.2019.04.004","volume":"93","author":"PM de Pauli","year":"2019","unstructured":"de Pauli PM, Ara\u00fajo ALD, Arboleda LPA, Palmier NR, Fons\u00eaca JM, Gomes-Silva W, et al. Tumor safety and side effects of photobiomodulation therapy used for prevention and management of cancer treatment toxicities. A systematic review. Oral Oncol. 2019;93:21\u20138.","journal-title":"Oral Oncol"},{"issue":"1","key":"961_CR136","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10103-016-2056-y","volume":"32","author":"J Robijns","year":"2017","unstructured":"Robijns J, Censabella S, Bulens P, Maes A, Mebis J. The use of low-level light therapy in supportive care for patients with breast cancer: review of the literature. Lasers Med Sci. 2017;32(1):229\u201342.","journal-title":"Lasers Med Sci"},{"issue":"1","key":"961_CR137","first-page":"41","volume":"32","author":"P Avci","year":"2013","unstructured":"Avci P, Gupta A, Sadasivam M, Vecchio D, Pam Z, Pam N, et al. Low-level laser (light) therapy (LLLT) in skin: stimulating, healing, restoring. Semin Cutan Med Surg. 2013;32(1):41\u201352.","journal-title":"Semin Cutan Med Surg"},{"key":"961_CR138","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jdrv.2024.09.004","volume":"2","author":"SM Perez","year":"2024","unstructured":"Perez SM, Williams KN, Nguyen B, Tosti A. Drugs and androgenetic alopecia: What to look out for. JAAD Rev. 2024;2:81\u20137.","journal-title":"JAAD Rev."},{"issue":"1","key":"961_CR139","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40257-020-00557-5","volume":"22","author":"NM Williams","year":"2021","unstructured":"Williams NM, Randolph M, Rajabi-Estarabadi A, Keri J, Tosti A. Hormonal contraceptives and dermatology. Am J Clin Dermatol. 2021;22(1):69\u201380.","journal-title":"Am J Clin Dermatol"},{"key":"961_CR140","unstructured":"Medical Eligibility Criteria for Contraceptive Use. Fifth ed. Geneva: World Health Organization; 2015."},{"issue":"5","key":"961_CR141","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jogoh.2019.02.006","volume":"48","author":"D Serfaty","year":"2019","unstructured":"Serfaty D. Update on the contraceptive contraindications. J Gynecol Obstet Hum Reprod. 2019;48(5):297\u2013307.","journal-title":"J Gynecol Obstet Hum Reprod."},{"issue":"23","key":"961_CR142","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1056\/NEJMoa1700732","volume":"377","author":"LS M\u00f8rch","year":"2017","unstructured":"M\u00f8rch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard \u00d8. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med. 2017;377(23):2228\u201339.","journal-title":"N Engl J Med"},{"key":"961_CR143","doi-asserted-by":"crossref","unstructured":"Phillips KA, Kotsopoulos J, Domchek SM, Terry MB, Chamberlain JA, Bassett JK, et al. Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2. J Clin Oncol. 2025;43(4):422\u201331.","DOI":"10.1200\/JCO.24.00176"},{"key":"961_CR144","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ejogrb.2020.12.035","volume":"258","author":"MK Ostroot","year":"2021","unstructured":"Ostroot MK, Heslin K, Kram JJF, Tjoe JA, Dorton B. Breast cancer recurrence risk after hormonal contraceptive use in survivors of reproductive age. Eur J Obstet Gynecol Reprod Biol. 2021;258:174\u20138.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"961_CR145","unstructured":"Supplements IoMUaNRCUCotFfEtSoD. Dietary Supplements: A Framework for Evaluating Safety. Washington (DC): National Academies Press (US); 2005."},{"issue":"6","key":"961_CR146","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s10068-019-00605-9","volume":"28","author":"Y Kwon","year":"2019","unstructured":"Kwon Y. Use of saw palmetto (Serenoa repens) extract for benign prostatic hyperplasia. Food Sci Biotechnol. 2019;28(6):1599\u2013606.","journal-title":"Food Sci Biotechnol."},{"key":"961_CR147","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.2147\/CCID.S435795","volume":"16","author":"HV Sudeep","year":"2023","unstructured":"Sudeep HV, Rashmi S, Jestin TV, Richards A, Gouthamchandra K, Shyamprasad K. Oral and topical administration of a standardized saw palmetto oil reduces hair fall and improves the hair growth in androgenetic alopecia subjects - a 16-week randomized, placebo-controlled study. Clin Cosmet Investig Dermatol. 2023;16:3251\u201366.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"6","key":"961_CR148","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1464-410X.1990.tb07199.x","volume":"66","author":"BE Carbin","year":"1990","unstructured":"Carbin BE, Larsson B, Lindahl O. Treatment of benign prostatic hyperplasia with phytosterols. Br J Urol. 1990;66(6):639\u201341.","journal-title":"Br J Urol"},{"issue":"1","key":"961_CR149","doi-asserted-by":"crossref","first-page":"549721","DOI":"10.1155\/2014\/549721","volume":"2014","author":"YH Cho","year":"2014","unstructured":"Cho YH, Lee SY, Jeong DW, Choi EJ, Kim YJ, Lee JG, et al. Effect of pumpkin seed oil on hair growth in men with androgenetic alopecia: a randomized, double-blind, placebo-controlled trial. Evidence-Based Complement Altern Med. 2014;2014(1):549721.","journal-title":"Evidence-Based Complement Altern Med."},{"issue":"11","key":"961_CR150","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.5966\/sctm.2015-0107","volume":"4","author":"P Gentile","year":"2015","unstructured":"Gentile P, Garcovich S, Bielli A, Scioli MG, Orlandi A, Cervelli V. The effect of platelet-rich plasma in hair regrowth: a randomized placebo-controlled trial. Stem Cells Transl Med. 2015;4(11):1317\u201323.","journal-title":"Stem Cells Transl Med"},{"issue":"4","key":"961_CR151","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00404-022-06416-4","volume":"306","author":"C Eichler","year":"2022","unstructured":"Eichler C, \u00dcner J, Thangarajah F, Radosa J, Zinser M, Fischer LA, et al. Platelet-rich plasma (PRP) in oncological patients: long-term oncological outcome analysis of the treatment of subcutaneous venous access device scars in 89 breast cancer patients. Arch Gynecol Obstet. 2022;306(4):1171\u20136.","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"961_CR152","doi-asserted-by":"crossref","first-page":"3432987","DOI":"10.1155\/2020\/3432987","volume":"2020","author":"C Eichler","year":"2020","unstructured":"Eichler C, Baucks C, \u00dcner J, Pahmeyer C, Ratiu D, Gruettner B, et al. Platelet-rich plasma (prp) in breast cancer patients: an application analysis of 163 sentinel lymph node biopsies. BioMed Res Int. 2020;2020(1):3432987.","journal-title":"BioMed Res Int"},{"key":"961_CR153","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.wneu.2020.01.230","volume":"137","author":"Y-f Liu","year":"2020","unstructured":"Liu Y-f, Liu L-y, Xia S-l, Li T, Li J. An unusual case of scalp metastasis from breast cancer. World Neurosurg. 2020;137:261\u20135.","journal-title":"World Neurosurg."},{"key":"961_CR154","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2147\/OTT.S456532","volume":"17","author":"J Wu","year":"2024","unstructured":"Wu J, Zhang W, Zhang H, Lu X, Luan B, Yang Q, et al. Scalp metastasis after breast cancer surgery: a case report. OncoTargets Therapy. 2024;17:411\u20139.","journal-title":"OncoTargets Therapy."},{"key":"961_CR155","doi-asserted-by":"crossref","first-page":"1382415","DOI":"10.3389\/fonc.2024.1382415","volume":"14","author":"J Yu","year":"2024","unstructured":"Yu J, Yao T, Zhang M, Li B, Yao Y. Case report: Advanced breast cancer with scalp metastases: a report of two cases. Front Oncol. 2024;14:1382415.","journal-title":"Front Oncol"},{"issue":"1","key":"961_CR156","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jaad.2020.03.087","volume":"83","author":"LJ Burns","year":"2020","unstructured":"Burns LJ, De Souza B, Flynn E, Hagigeorges D, Senna MM. Spironolactone for treatment of female pattern hair loss. J Am Acad Dermatol. 2020;83(1):276\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"961_CR157","unstructured":"Patibandla S, Heaton J, Kyaw H. Spironolactone. [Updated 2023 Jul 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554421\/. Accessed 30 Apr 2025."},{"issue":"2","key":"961_CR158","volume":"9","author":"MG Buontempo","year":"2023","unstructured":"Buontempo MG, Alhanshali L, Shapiro J, Lo SK. Exploring the historical stigma of spironolactone use in breast cancer survivors with alopecia. Int J Womens Dermatol. 2023;9(2): e083.","journal-title":"Int J Womens Dermatol."},{"issue":"7930","key":"961_CR159","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0140-6736(75)92814-7","volume":"306","author":"H Jick","year":"1975","unstructured":"Jick H, Armstrong B. Breast cancer and spironolactone. The Lancet. 1975;306(7930):368\u20139.","journal-title":"The Lancet"},{"key":"961_CR160","unstructured":"Oppermann J, Piper C, Gardiner P, Mutschler E. Therapie Mit Aldosteron-Antagonisten. 1988."},{"issue":"3","key":"961_CR161","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/BF00316635","volume":"61","author":"CS Cook","year":"1988","unstructured":"Cook CS, Hauswald CL, Schoenhard GL, Piper CE, Patel A, Radzialowski FM, et al. Difference in metabolic profile of potassium canrenoate and spironolactone in the rat: mutagenic metabolites unique to potassium canrenoate. Arch ToxicoL. 1988;61(3):201\u201312.","journal-title":"Arch ToxicoL"},{"key":"961_CR162","unstructured":"Oppermann J, Piper C, Gardiner P, Mutschler E. Spironolactone and potassium canrenoate\u2013despite chemical similarities, differing metabolism accounts for different toxicological findings in animals. Therapie Mit Aldosteron-Antagonisten Ed Mutschler E M\u00fcnchen-Wien-Baltimore: Urban & Scharzenberg. 1988."},{"issue":"6","key":"961_CR163","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.jaad.2024.01.057","volume":"90","author":"RC Hill","year":"2024","unstructured":"Hill RC, Wang Y, Shaikh B, Ong M, Christos PJ, Lipner SR. Spironolactone treatment for dermatologic indications is not associated with hypotension in a single-center retrospective study. J Am Acad Dermatol. 2024;90(6):1245\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"961_CR164","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamadermatol.2021.5866","volume":"158","author":"K Bommareddy","year":"2022","unstructured":"Bommareddy K, Hamade H, Lopez-Olivo MA, Wehner M, Tosh T, Barbieri JS. Association of spironolactone use with risk of cancer: a systematic review and meta-analysis. JAMA Dermatol. 2022;158(3):275\u201382.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"961_CR165","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.canep.2013.10.004","volume":"37","author":"RJ Biggar","year":"2013","unstructured":"Biggar RJ, Andersen EW, Wohlfahrt J, Melbye M. Spironolactone use and the risk of breast and gynecologic cancers. Cancer Epidemiol. 2013;37(6):870\u20135.","journal-title":"Cancer Epidemiol"},{"issue":"6","key":"961_CR166","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1001\/jamadermatol.2018.0454","volume":"154","author":"A Freites-Martinez","year":"2018","unstructured":"Freites-Martinez A, Shapiro J, Chan D, Fornier M, Modi S, Gajria D, et al. Endocrine therapy-induced alopecia in patients with breast cancer. JAMA Dermatol. 2018;154(6):670\u20135.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"961_CR167","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jaad.2020.05.081","volume":"83","author":"C Wei","year":"2020","unstructured":"Wei C, Bovonratwet P, Gu A, Moawad G, Silverberg JI, Friedman AJ. Spironolactone use does not increase the risk of female breast cancer recurrence: a retrospective analysis. J Am Acad Dermatol. 2020;83(4):1021\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"961_CR168","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/ced.14292","volume":"45","author":"HY Sun","year":"2020","unstructured":"Sun HY, Sebaratnam DF. Clascoterone as a novel treatment for androgenetic alopecia. Clin Exp Dermatol. 2020;45(7):913\u20134.","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"961_CR169","first-page":"197","volume":"18","author":"C Rosette","year":"2019","unstructured":"Rosette C, Rosette N, Mazzetti A, Moro L, Gerloni M. Cortexolone 17\u03b1-propionate (clascoterone) is an androgen receptor antagonist in dermal papilla cells in vitro. J Drugs Dermatol. 2019;18(2):197\u2013201.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"961_CR170","first-page":"563","volume":"18","author":"A Mazzetti","year":"2019","unstructured":"Mazzetti A, Moro L, Gerloni M, Cartwright M. Pharmacokinetic profile, safety, and tolerability of clascoterone (cortexolone 17-alpha propionate, CB-03-01) topical cream, 1% in subjects with acne vulgaris: an open-label phase 2a study. J Drugs Dermatol. 2019;18(6):563.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"961_CR171","first-page":"570","volume":"18","author":"A Mazzetti","year":"2019","unstructured":"Mazzetti A, Moro L, Gerloni M, Cartwright M. A phase 2b, randomized, double-blind vehicle controlled, dose escalation study evaluating clascoterone 0.1%, 0.5%, and 1% topical cream in subjects with facial acne. J Drugs Dermatol. 2019;18(6):570.","journal-title":"J Drugs Dermatol"},{"issue":"8","key":"961_CR172","doi-asserted-by":"crossref","first-page":"810","DOI":"10.36849\/jdd.7592","volume":"22","author":"LF Eichenfield","year":"2023","unstructured":"Eichenfield LF, Hebert AA, Gold LS, Cartwright M, Moro L, Han J, et al. Long-term safety and efficacy of twice-daily topical clascoterone cream 1% in patients greater than or equal to 12 years of age with acne vulgaris. J Drugs Dermatol. 2023;22(8):810\u20136.","journal-title":"J Drugs Dermatol"},{"key":"961_CR173","unstructured":"Sun Pharmaceutical Industries, Inc. WINLEVI (clascoterone) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/213433Orig1s002lbl.pdf. Revised March 2022. Accessed 24 Oct 2024."},{"issue":"8","key":"961_CR174","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s40265-023-01880-x","volume":"83","author":"S Devjani","year":"2023","unstructured":"Devjani S, Ezemma O, Kelley KJ, Stratton E, Senna M. Androgenetic alopecia: therapy update. Drugs. 2023;83(8):701\u201315.","journal-title":"Drugs"},{"key":"961_CR175","unstructured":"ClincalTrials.gov [Internet]. NCT05910450. A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP1) . Updated August 8, 2024. https:\/\/clinicaltrials.gov\/study\/NCT05910450."},{"issue":"8","key":"961_CR176","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s13555-023-00974-4","volume":"13","author":"M Escamilla-Cruz","year":"2023","unstructured":"Escamilla-Cruz M, Maga\u00f1a M, Escand\u00f3n-Perez S, Bello-Chavolla OY. Use of 5-alpha reductase inhibitors in dermatology: a narrative review. Dermatol Ther (Heidelb). 2023;13(8):1721\u201331.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"4","key":"961_CR177","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaad.2013.12.003","volume":"70","author":"S Va\u00f1\u00f3-Galv\u00e1n","year":"2014","unstructured":"Va\u00f1\u00f3-Galv\u00e1n S, Molina-Ruiz AM, Serrano-Falc\u00f3n C, Arias-Santiago S, Rodrigues-Barata AR, Garnacho-Saucedo G, et al. Frontal fibrosing alopecia: a multicenter review of 355 patients. J Am Acad Dermatol. 2014;70(4):670\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"961_CR178","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/ced.13203","volume":"42","author":"F Mardones","year":"2017","unstructured":"Mardones F, Shapiro J. Lichen planopilaris in a Latin American (Chilean) population: demographics, clinical profile and treatment experience. Clin Exp Dermatol. 2017;42(7):755\u20139.","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"961_CR179","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s40257-021-00630-7","volume":"22","author":"K Svigos","year":"2021","unstructured":"Svigos K, Yin L, Fried L, Lo Sicco K, Shapiro J. A Practical approach to the diagnosis and management of classic lichen planopilaris. Am J Clin Dermatol. 2021;22(5):681\u201392.","journal-title":"Am J Clin Dermatol"},{"key":"961_CR180","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2147\/IJWH.S177308","volume":"11","author":"AC Gamret","year":"2019","unstructured":"Gamret AC, Potluri VS, Krishnamurthy K, Fertig RM. Frontal fibrosing alopecia: efficacy of treatment modalities. Int J Womens Health. 2019;11:273\u201385.","journal-title":"Int J Womens Health."},{"issue":"3","key":"961_CR181","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/MJT.0b013e31818a975c","volume":"16","author":"D Pariser","year":"2009","unstructured":"Pariser D. Topical corticosteroids and topical calcineurin inhibitors in the treatment of atopic dermatitis: focus on percutaneous absorption. Am J Ther. 2009;16(3):264\u201373.","journal-title":"Am J Ther"},{"issue":"3","key":"961_CR182","doi-asserted-by":"crossref","first-page":"165","DOI":"10.5114\/pdia.2013.35619","volume":"30","author":"K Gutfreund","year":"2013","unstructured":"Gutfreund K, Bienias W, Szewczyk A, Kaszuba A. Topical calcineurin inhibitors in dermatology. Part I: properties, method and effectiveness of drug use. Postepy Dermatol Alergol. 2013;30(3):165\u20139.","journal-title":"Postepy Dermatol Alergol."},{"issue":"1","key":"961_CR183","doi-asserted-by":"crossref","first-page":"46","DOI":"10.4048\/jbc.2023.26.e2","volume":"26","author":"FC Gulmark Hansen","year":"2023","unstructured":"Gulmark Hansen FC, J\u00f8rgensen MG, S\u00f8rensen JA. Treatment of breast cancer-related lymphedema with topical tacrolimus: a prospective, open-label, single-arm, phase II pilot trial. J Breast Cancer. 2023;26(1):46\u201359.","journal-title":"J Breast Cancer"},{"issue":"1","key":"961_CR184","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S2352-4642(22)00283-8","volume":"7","author":"N Devasenapathy","year":"2023","unstructured":"Devasenapathy N, Chu A, Wong M, Srivastava A, Ceccacci R, Lin C, et al. Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis. Lancet Child Adolesc Health. 2023;7(1):13\u201325.","journal-title":"Lancet Child Adolesc Health."},{"issue":"3","key":"961_CR185","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.abd.2021.08.008","volume":"97","author":"COC Fechine","year":"2022","unstructured":"Fechine COC, Valente NYS, Romiti R. Lichen planopilaris and frontal fibrosing alopecia: review and update of diagnostic and therapeutic features. An Bras Dermatol. 2022;97(3):348\u201357.","journal-title":"An Bras Dermatol"},{"issue":"6","key":"961_CR186","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jaad.2023.12.073","volume":"90","author":"T Jackson","year":"2024","unstructured":"Jackson T, Sow Y, Dinkins J, Aguh C, Omueti Ayoade K, Barbosa V, et al. Treatment for central centrifugal cicatricial alopecia-Delphi consensus recommendations. J Am Acad Dermatol. 2024;90(6):1182\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"961_CR187","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jaad.2009.03.027","volume":"61","author":"A Menter","year":"2009","unstructured":"Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61(3):451\u201385.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"961_CR188","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","volume":"80","author":"CA Elmets","year":"2019","unstructured":"Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073\u2013113.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"961_CR189","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jdcr.2015.06.013","volume":"1","author":"CA Chen","year":"2015","unstructured":"Chen CA, Costa DB, Wu PA. Successful treatment of epidermal growth factor receptor inhibitor-induced alopecia with doxycycline. JAAD Case Rep. 2015;1(5):289\u201391.","journal-title":"JAAD Case Rep."},{"issue":"2","key":"961_CR190","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jaad.2024.01.086","volume":"91","author":"A Obi","year":"2024","unstructured":"Obi A, McKinley J, Oladunjoye E, Williams A, Li V, Wu J, et al. Doxycycline for central centrifugal cicatricial alopecia: a single center retrospective analysis. J Am Acad Dermatol. 2024;91(2):331\u20133.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"961_CR191","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12943-017-0607-x","volume":"16","author":"X Tang","year":"2017","unstructured":"Tang X, Wang X, Zhao YY, Curtis JM, Brindley DN. Doxycycline attenuates breast cancer related inflammation by decreasing plasma lysophosphatidate concentrations and inhibiting NF-\u03baB activation. Mol Cancer. 2017;16(1):36.","journal-title":"Mol Cancer"},{"issue":"8","key":"961_CR192","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/15384101.2016.1241929","volume":"16","author":"L Zhang","year":"2017","unstructured":"Zhang L, Xu L, Zhang F, Vlashi E. Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast cancer. Cell Cycle. 2017;16(8):737\u201345.","journal-title":"Cell Cycle"},{"key":"961_CR193","doi-asserted-by":"crossref","first-page":"1028926","DOI":"10.3389\/fphar.2022.1028926","volume":"13","author":"S Brown","year":"2022","unstructured":"Brown S, Dayan JH, Coriddi M, McGrath L, Kataru RP, Mehrara BJ. Doxycycline for the treatment of breast cancer-related lymphedema. Front Pharmacol. 2022;13:1028926.","journal-title":"Front Pharmacol"},{"issue":"6","key":"961_CR194","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","volume":"123","author":"MF Marmor","year":"2016","unstructured":"Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123(6):1386\u201394.","journal-title":"Ophthalmology"},{"issue":"12","key":"961_CR195","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","volume":"132","author":"RB Melles","year":"2014","unstructured":"Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132(12):1453\u201360.","journal-title":"JAMA Ophthalmol."},{"key":"961_CR196","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2147\/TCRM.S175581","volume":"14","author":"IC Mao","year":"2018","unstructured":"Mao IC, Lin CY, Wu CL, Kor CT, Chang CC. Hydroxychloroquine and risk of development of cancers: a nationwide population-based cohort study. Ther Clin Risk Manag. 2018;14:1435\u201343.","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"961_CR197","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1124\/jpet.121.000730","volume":"379","author":"KM Van Eaton","year":"2021","unstructured":"Van Eaton KM, Gustafson DL. Pharmacokinetic and pharmacodynamic assessment of hydroxychloroquine in breast cancer. J Pharmacol Exp Ther. 2021;379(3):331\u201342.","journal-title":"J Pharmacol Exp Ther"},{"key":"961_CR198","unstructured":"ClinicalTrials.gov [Internet]. NCT04841148. Avelumab or Hydroxychloroquine with or Without Palbociclib to Eliminate Dormant Breast Cancer (PALAVY). Updated March 11, 2025. https:\/\/clinicaltrials.gov\/study\/NCT04841148."},{"issue":"2","key":"961_CR199","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s10549-019-05381-y","volume":"178","author":"A Arnaout","year":"2019","unstructured":"Arnaout A, Robertson SJ, Pond GR, Lee H, Jeong A, Ianni L, et al. A randomized, double-blind, window of opportunity trial evaluating the effects of chloroquine in breast cancer patients. Breast Cancer Res Treat. 2019;178(2):327\u201335.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"961_CR200","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/15563650.2020.1817479","volume":"59","author":"C Doyno","year":"2021","unstructured":"Doyno C, Sobieraj DM, Baker WL. Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose. Clin Toxicol. 2021;59(1):12\u201323.","journal-title":"Clin Toxicol"},{"issue":"6","key":"961_CR201","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s13555-024-01166-4","volume":"14","author":"M Mansilla-Polo","year":"2024","unstructured":"Mansilla-Polo M, Morgado-Carrasco D. Biologics versus JAK inhibitors. Part I: cancer risk. A narrative review. Dermatol Ther (Heidelb). 2024;14(6):1389\u2013442.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"2","key":"961_CR202","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jdcr.2019.12.008","volume":"6","author":"EF Araoye","year":"2020","unstructured":"Araoye EF, Thomas JAL, Aguh CU. Hair regrowth in 2 patients with recalcitrant central centrifugal cicatricial alopecia after use of topical metformin. JAAD Case Rep. 2020;6(2):106\u20138.","journal-title":"JAAD Case Rep."},{"key":"961_CR203","doi-asserted-by":"crossref","unstructured":"Granja BV, De Matos PR, Rosa GP, Pinheiro J, Azevedo F, Pedrosa AF. Treatment of central centrifugal cicatricial alopecia with topical metformin 10% cream: case report and literature review. Int J Dermatol. 2025;64(1):213\u20135.","DOI":"10.1111\/ijd.17345"},{"key":"961_CR204","doi-asserted-by":"crossref","unstructured":"Bao A, Qadri A, Gadre A, Will E, Collins D, Ahima R, et al. Low-Dose Metformin and Profibrotic Signature in Central Centrifugal Cicatricial Alopecia. JAMA Dermatol. 2024;160(11):1211\u20139.","DOI":"10.1001\/jamadermatol.2024.3062"},{"issue":"9","key":"961_CR205","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","volume":"60","author":"G Rena","year":"2017","unstructured":"Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577\u201385.","journal-title":"Diabetologia"},{"issue":"1","key":"961_CR206","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12967-021-02860-z","volume":"19","author":"J Moon","year":"2021","unstructured":"Moon J, Lee SY, Choi JW, Lee AR, Yoo JH, Moon SJ, et al. Metformin ameliorates scleroderma via inhibiting Th17 cells and reducing mTOR-STAT3 signaling in skin fibroblasts. J Transl Med. 2021;19(1):192.","journal-title":"J Transl Med"},{"issue":"4","key":"961_CR207","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/SAP.0000000000002574","volume":"86","author":"HB Jeon","year":"2021","unstructured":"Jeon HB, Roh H, Ahn HM, Lee JH, Yun CO, Roh TS, et al. Metformin inhibits transforming growth factor \u03b2-induced fibrogenic response of human dermal fibroblasts and suppresses fibrosis in keloid spheroids. Ann Plast Surg. 2021;86(4):406\u201311.","journal-title":"Ann Plast Surg"},{"issue":"1","key":"961_CR208","first-page":"6673525","volume":"2021","author":"M Wu","year":"2021","unstructured":"Wu M, Xu H, Liu J, Tan X, Wan S, Guo M, et al. Metformin and fibrosis: a review of existing evidence and mechanisms. J Diabetes Res. 2021;2021(1):6673525.","journal-title":"J Diabetes Res"},{"issue":"3","key":"961_CR209","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.annonc.2020.12.008","volume":"32","author":"YMM Park","year":"2021","unstructured":"Park YMM, Bookwalter DB, O\u2019Brien KM, Jackson CL, Weinberg CR, Sandler DP. A prospective study of type 2 diabetes, metformin use, and risk of breast cancer. Ann Oncol. 2021;32(3):351\u20139.","journal-title":"Ann Oncol"},{"issue":"20","key":"961_CR210","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2009.22.1630","volume":"27","author":"PJ Goodwin","year":"2009","unstructured":"Goodwin PJ, Ligibel JA, Stambolic V. Metformin in breast cancer: time for action. J Clin Oncol. 2009;27(20):3271\u20133.","journal-title":"J Clin Oncol"},{"issue":"6","key":"961_CR211","doi-asserted-by":"crossref","first-page":"909","DOI":"10.4161\/cc.8.6.7933","volume":"8","author":"IN Alimova","year":"2009","unstructured":"Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle. 2009;8(6):909\u201315.","journal-title":"Cell Cycle"},{"issue":"21","key":"961_CR212","doi-asserted-by":"crossref","first-page":"10269","DOI":"10.1158\/0008-5472.CAN-06-1500","volume":"66","author":"M Zakikhani","year":"2006","unstructured":"Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase\u2013dependent growth inhibitor for breast cancer cells. Cancer Res. 2006;66(21):10269\u201373.","journal-title":"Cancer Res"},{"issue":"3","key":"961_CR213","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.annonc.2020.12.014","volume":"32","author":"AE Lohmann","year":"2021","unstructured":"Lohmann AE, Goodwin PJ. Diabetes, metformin and breast cancer: a tangled web. Ann Oncol. 2021;32(3):285\u20136.","journal-title":"Ann Oncol"},{"issue":"2","key":"961_CR214","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/abbs\/gmx106","volume":"50","author":"N Saini","year":"2018","unstructured":"Saini N, Yang X. Metformin as an anti-cancer agent: actions and mechanisms targeting cancer stem cells. Acta Biochim Biophys Sin. 2018;50(2):133\u201343.","journal-title":"Acta Biochim Biophys Sin"},{"issue":"3","key":"961_CR215","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s10549-012-2170-x","volume":"135","author":"NF Col","year":"2012","unstructured":"Col NF, Ochs L, Springmann V, Aragaki AK, Chlebowski RT. Metformin and breast cancer risk: a meta-analysis and critical literature review. Breast Cancer Res Treat. 2012;135(3):639\u201346.","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"961_CR216","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1093\/annonc\/mdw410","volume":"27","author":"C Coyle","year":"2016","unstructured":"Coyle C, Cafferty FH, Vale C, Langley RE. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann Oncol. 2016;27(12):2184\u201395.","journal-title":"Ann Oncol"},{"issue":"6","key":"961_CR217","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1158\/1055-9965.EPI-17-0936","volume":"27","author":"GH Tang","year":"2018","unstructured":"Tang GH, Satkunam M, Pond GR, Steinberg GR, Blandino G, Sch\u00fcnemann HJ, et al. Association of metformin with breast cancer incidence and mortality in patients with type II diabetes: a GRADE-assessed systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prevention. 2018;27(6):627\u201335.","journal-title":"Cancer Epidemiol Biomarkers Prevention."},{"issue":"3","key":"961_CR218","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/jcpt.13500","volume":"47","author":"Q Wang","year":"2022","unstructured":"Wang Q, Ma X, Long J, Du X, Pan B, Mao H. Metformin and survival of women with breast cancer: a meta-analysis of randomized controlled trials. J Clin Pharm Ther. 2022;47(3):263\u20139.","journal-title":"J Clin Pharm Ther"},{"issue":"20","key":"961_CR219","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.2022.6147","volume":"327","author":"PJ Goodwin","year":"2022","unstructured":"Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J, et al. Effect of metformin vs placebo on invasive disease-free survival in patients with breast cancer: the MA.32 randomized clinical trial. JAMA. 2022;327(20):1963\u201373.","journal-title":"JAMA"},{"issue":"1","key":"961_CR220","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcjd.2023.07.008","volume":"48","author":"L Scott","year":"2024","unstructured":"Scott L, Truong L-L, Houlden RL, Wijeratne DT. Screening and management recommendations for type 2 diabetes in women with breast cancer. Can J Diabetes. 2024;48(1):66\u201372.","journal-title":"Can J Diabetes"},{"issue":"3","key":"961_CR221","first-page":"146","volume":"23","author":"N Ly","year":"2024","unstructured":"Ly N, McClure EM, Hordinsky MK, Farah RS, Park SY. Safety and efficacy of minoxidil treatment in scarring alopecia: a scoping review. J Drugs Dermatol. 2024;23(3):146\u201351.","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"961_CR222","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1529-8019.2007.00136.x","volume":"20","author":"J Zwerner","year":"2007","unstructured":"Zwerner J, Fiorentino D. Mycophenolate mofetil. Dermatol Ther. 2007;20(4):229\u201338.","journal-title":"Dermatol Ther"},{"issue":"1","key":"961_CR223","volume":"2014","author":"N Majd","year":"2014","unstructured":"Majd N, Sumita K, Yoshino H, Chen D, Terakawa J, Daikoku T, et al. A review of the potential utility of mycophenolate mofetil as a cancer therapeutic. J Cancer Res. 2014;2014(1): 423401.","journal-title":"J Cancer Res"},{"issue":"673","key":"961_CR224","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bbrc.2023.06.069","volume":"17","author":"Y Takizawa","year":"2023","unstructured":"Takizawa Y, Kizawa M, Niwa N, Komura Y, Takahashi M, Koda D, et al. Specific inhibitory effects of guanosine on breast cancer cell proliferation. Biochem Biophys Res Commun. 2023;17(673):67\u201372.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"961_CR225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2011.01.068","volume":"658","author":"Z-H Zheng","year":"2011","unstructured":"Zheng Z-H, Yang Y, Lu X-H, Zhang H, Shui X-X, Liu C, et al. Mycophenolic acid induces adipocyte-like differentiation and reversal of malignancy of breast cancer cells partly through PPAR\u03b3. Eur J Pharmacol. 2011;658(1):1\u20138.","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"961_CR226","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.31557\/APJCP.2018.19.12.3551","volume":"19","author":"RA Cader","year":"2018","unstructured":"Cader RA, Mei Yee AK, Yassin A, Ahmad I, Haron SN. Malignancy in systemic lupus erythematosus (SLE) patients. Asian Pac J Cancer Prev. 2018;19(12):3551\u20135.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"2","key":"961_CR227","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/bcp.14979","volume":"88","author":"P Hirunsatitpron","year":"2022","unstructured":"Hirunsatitpron P, Hanprasertpong N, Noppakun K, Pruksakorn D, Teekachunhatean S, Koonrungsesomboon N. Mycophenolic acid and cancer risk in solid organ transplant recipients: systematic review and meta-analysis. Br J Clin Pharmacol. 2022;88(2):476\u201389.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"961_CR228","volume":"15","author":"RK Hamel","year":"2023","unstructured":"Hamel RK, Chen L, O\u2019Connell C, Mann C. Oral low-dose naltrexone in the treatment of frontal fibrosing alopecia and lichen planopilaris: an uncontrolled open-label prospective study. Cureus. 2023;15(1):e34169.","journal-title":"Cureus."},{"key":"961_CR229","doi-asserted-by":"crossref","unstructured":"Ciwun M, Tankiewicz-Kwedlo A, Pawlak D. Low-dose naltrexone as an adjuvant in combined anticancer therapy. Cancers (Basel). 2024;16(6).","DOI":"10.3390\/cancers16061240"},{"issue":"1","key":"961_CR230","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s10637-022-01317-4","volume":"41","author":"J Vijayakumar","year":"2023","unstructured":"Vijayakumar J, Haddad T, Gupta K, Sauers J, Yee D. An open label phase II study of safety and clinical activity of naltrexone for treatment of hormone refractory metastatic breast cancer. Invest N Drugs. 2023;41(1):70\u20135.","journal-title":"Invest N Drugs."},{"issue":"2","key":"961_CR231","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/0006-291X(91)91611-F","volume":"175","author":"H Abou-Issa","year":"1991","unstructured":"Abou-Issa H, Tejwani GA. Antitumor activity of naltrexone and correlation with steroid hormone receptors. Biochem Biophys Res Commun. 1991;175(2):625\u201330.","journal-title":"Biochem Biophys Res Commun"},{"key":"961_CR232","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jdcr.2022.07.038","volume":"28","author":"M Karim","year":"2022","unstructured":"Karim M, Klein EJ, Brinster N, Rieder E, Lo Sicco K, Shapiro J. Reversible hair loss in a patient with cicatricial alopecia: a case of regrowth associated with pioglitazone use. JAAD Case Rep. 2022;28:21\u20133.","journal-title":"JAAD Case Rep."},{"issue":"3","key":"961_CR233","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2015.7996","volume":"314","author":"JD Lewis","year":"2015","unstructured":"Lewis JD, Habel LA, Quesenberry CP, Strom BL, Peng T, Hedderson MM, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA. 2015;314(3):265\u201377.","journal-title":"JAMA"},{"issue":"4","key":"961_CR234","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/cam4.1354","volume":"7","author":"H Tang","year":"2018","unstructured":"Tang H, Shi W, Fu S, Wang T, Zhai S, Song Y, et al. Pioglitazone and bladder cancer risk: a systematic review and meta-analysis. Cancer Med. 2018;7(4):1070\u201380.","journal-title":"Cancer Med"},{"issue":"4","key":"961_CR235","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s13300-017-0273-4","volume":"8","author":"E Filipova","year":"2017","unstructured":"Filipova E, Uzunova K, Kalinov K, Vekov T. Pioglitazone and the risk of bladder cancer: a meta-analysis. Diabetes Ther. 2017;8(4):705\u201326.","journal-title":"Diabetes Ther."},{"issue":"3","key":"961_CR236","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/00002018-200932030-00002","volume":"32","author":"J Dormandy","year":"2009","unstructured":"Dormandy J, Bhattacharya M. de Bruyn A-RvT, on behalf of the Pi. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes. Drug Saf. 2009;32(3):187\u2013202.","journal-title":"Drug Saf"},{"issue":"1","key":"961_CR237","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1186\/s12885-022-09660-8","volume":"22","author":"CH Tseng","year":"2022","unstructured":"Tseng CH. Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis. BMC Cancer. 2022;22(1):559.","journal-title":"BMC Cancer"},{"key":"961_CR238","volume-title":"Breast Cancer Facts & Figures 2024\u20132024","author":"American Cancer Society","year":"2024","unstructured":"American Cancer Society. Breast Cancer Facts & Figures 2024\u20132024. Atlanta: American Cancer Society; 2024."},{"issue":"2","key":"961_CR239","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/ajd.12941","volume":"60","author":"WC Cranwell","year":"2019","unstructured":"Cranwell WC, Lai VW, Photiou L, Meah N, Wall D, Rathnayake D, et al. Treatment of alopecia areata: an Australian expert consensus statement. Australas J Dermatol. 2019;60(2):163\u201370.","journal-title":"Australas J Dermatol"},{"issue":"4","key":"961_CR240","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/jdv.19768","volume":"38","author":"L Rudnicka","year":"2024","unstructured":"Rudnicka L, Arenbergerova M, Grimalt R, Ioannides D, Katoulis AC, Lazaridou E, et al. European expert consensus statement on the systemic treatment of alopecia areata. J Eur Acad Dermatol Venereol. 2024;38(4):687\u201394.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"961_CR241","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s40257-023-00808-1","volume":"24","author":"D Dahabreh","year":"2023","unstructured":"Dahabreh D, Jung S, Renert-Yuval Y, Bar J, Del Duca E, Guttman-Yassky E. Alopecia areata: current treatments and new directions. Am J Clin Dermatol. 2023;24(6):895\u2013912.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"961_CR242","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jaad.2021.08.043","volume":"86","author":"BA King","year":"2022","unstructured":"King BA, Mesinkovska NA, Craiglow B, Kindred C, Ko J, McMichael A, et al. Development of the alopecia areata scale for clinical use: Results of an academic\u2013industry collaborative effort. J Am Acad Dermatol. 2022;86(2):359\u201364.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"961_CR243","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1111\/jocd.14537","volume":"20","author":"MS Nestor","year":"2021","unstructured":"Nestor MS, Ablon G, Gade A, Han H, Fischer DL. Treatment options for androgenetic alopecia: efficacy, side effects, compliance, financial considerations, and ethics. J Cosmet Dermatol. 2021;20(12):3759\u201381.","journal-title":"J Cosmet Dermatol"},{"issue":"1","key":"961_CR244","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/jdv.14624","volume":"32","author":"V Kanti","year":"2018","unstructured":"Kanti V, Messenger A, Dobos G, Reygagne P, Finner A, Blumeyer A, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men-short version. J Eur Acad Dermatol Venereol. 2018;32(1):11\u201322.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"961_CR245","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.abd.2022.09.006","volume":"98","author":"P M\u00fcller Ramos","year":"2023","unstructured":"M\u00fcller Ramos P, Melo DF, Radwanski H, de Almeida RFC, Miot HA. Female-pattern hair loss: therapeutic update. An Bras Dermatol. 2023;98(4):506\u201319.","journal-title":"An Bras Dermatol"},{"key":"961_CR246","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40257-019-00479-x","volume":"21","author":"M Starace","year":"2020","unstructured":"Starace M, Orlando G, Alessandrini A, Piraccini BM. Female androgenetic alopecia: an update on diagnosis and management. Am J Clin Dermatol. 2020;21:69\u201384.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"961_CR247","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/jvc2.53","volume":"1","author":"M Dominguez-Santas","year":"2022","unstructured":"Dominguez-Santas M, Diaz-Guimaraens B, Saceda-Corralo D, Hermosa-Gelbard A, Mu\u00f1oz-Moreno Arrones O, Pindado-Ortega C, et al. The state-of-the-art in the management of androgenetic alopecia: a review of new therapies and treatment algorithms. JEADV Clin Pract. 2022;1(3):176\u201385.","journal-title":"JEADV Clin Pract."},{"issue":"2","key":"961_CR248","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jaad.2019.03.079","volume":"81","author":"A Ho","year":"2019","unstructured":"Ho A, Shapiro J. Medical therapy for frontal fibrosing alopecia: a review and clinical approach. J Am Acad Dermatol. 2019;81(2):568\u201380.","journal-title":"J Am Acad Dermatol"},{"key":"961_CR249","doi-asserted-by":"crossref","unstructured":"Ezzat R, Alenezi S, Miteva M. Frontal fibrosing alopecia Part II: Etiopathogenesis and management. J Am Acad Dermatol. 2025 Jan 10:S0190-9622(25)00041-6. doi:10.1016\/j.jaad.2024.08.086. Epub ahead of print. PMID: 39800209.","DOI":"10.1016\/j.jaad.2024.08.086"},{"key":"961_CR250","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2147\/CCID.S137870","volume":"11","author":"E Errichetti","year":"2018","unstructured":"Errichetti E, Matteo F, Margherita C, Stinco G. Therapeutic management of classic lichen planopilaris: a systematic review. Clin Cosmetic Invest Dermatol. 2018;11:91\u2013102.","journal-title":"Clin Cosmetic Invest Dermatol."},{"issue":"8","key":"961_CR251","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamadermatol.2024.1445","volume":"160","author":"N Pelet del Toro","year":"2024","unstructured":"Pelet del Toro N, Strunk A, Garg A, Han G. Prevalence and treatment patterns in patients with lichen planopilaris. JAMA Dermatol. 2024;160(8):865\u20138.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"961_CR252","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s13555-024-01186-0","volume":"14","author":"M Starace","year":"2024","unstructured":"Starace M, Cedirian S, Rapparini L, Quadrelli F, Pampaloni F, Bruni F, et al. Enhanced insights into frontal fibrosing alopecia: advancements in pathogenesis understanding and management strategies. Dermatol Therapy. 2024;14(6):1457\u201377.","journal-title":"Dermatol Therapy."},{"issue":"1","key":"961_CR253","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/jdv.19426","volume":"38","author":"S Yoon","year":"2024","unstructured":"Yoon S, Kim K, Shin K, Kim H-S, Kim B, Kim M-B, et al. The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2024;38(1):52\u201361.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"961_CR254","doi-asserted-by":"crossref","unstructured":"Liubchenko K, Kordbacheh K, Khajehdehi N, Visnjevac T, Ma F, Khan JS, et al. Naltrexone\u2019s Impact on Cancer Progression and Mortality: A Systematic Review of Studies in Humans, Animal Models, and Cell Cultures. Advances in Therapy. 2021;38(2):904\u201324.","DOI":"10.1007\/s12325-020-01591-9"},{"key":"961_CR255","unstructured":"ClinicalTrials.gov [Internet]. NCT04523857. ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer (ABBY). Updated April 4, 2025. https:\/\/clinicaltrials.gov\/study\/NCT04523857."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00961-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-00961-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00961-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T15:46:08Z","timestamp":1763048768000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-00961-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":255,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["961"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-00961-9","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"15 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"IRB Approval"}},{"value":"No funds, grants, or other support was received for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no relevant conflicts of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Statement"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient Consent"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Conceptualization: Kristen I. Lo Sicco, MD; Literature review: Caitlin A. Kearney, BS, Anna L. Brinks, BA, Carli D. Needle, BA, Grace Rachko, BA; Drafting of the manuscript: Caitlin A. Kearney, BS, Anna L. Brinks, BA, Carli D. Needle, BA; Critical revision of the manuscript: Amy K. Bieber; MD, Jerry Shapiro, MD; Mario E. Lacouture, MD; Daniela Majerson, MD; Kristen I. Lo Sicco, MD; Supervision: Kristen I. Lo Sicco, MD. All authors read and approved the final manuscript.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contribution Statement"}}]}}